Allison Bratzel
Stock Analyst at Piper Sandler
(4.45)
# 363
Out of 5,182 analysts
60
Total ratings
63.27%
Success rate
17.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HUMA Humacyte | Maintains: Neutral | $3 → $1 | $0.71 | +40.81% | 3 | Mar 30, 2026 | |
| MGTX MeiraGTx Holdings | Maintains: Overweight | $30 → $26 | $10.12 | +156.92% | 2 | Mar 27, 2026 | |
| TYRA Tyra Biosciences | Maintains: Overweight | $42 → $56 | $35.56 | +57.48% | 3 | Mar 20, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $51 → $58 | $49.96 | +16.09% | 5 | Mar 4, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $87 → $100 | $75.71 | +32.08% | 5 | Feb 27, 2026 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $35 → $38 | $40.77 | -6.79% | 4 | Feb 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $84 | $54.64 | +53.73% | 1 | Feb 6, 2026 | |
| INCY Incyte | Maintains: Overweight | $102 → $110 | $97.82 | +12.45% | 4 | Feb 6, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $6 → $4 | $1.41 | +184.70% | 2 | Feb 6, 2026 | |
| REPL Replimune Group | Maintains: Overweight | $13 → $14 | $2.17 | +545.16% | 3 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.67 | +139.52% | 1 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $820 → $930 | $849.04 | +9.54% | 15 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $112 | $120.16 | -6.79% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $24.81 | +363.52% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $8.07 | +222.18% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $32.43 | -29.08% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $29.83 | -26.25% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $8.63 | +131.75% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $4.01 | +398.75% | 1 | Oct 13, 2023 |
Humacyte
Mar 30, 2026
Maintains: Neutral
Price Target: $3 → $1
Current: $0.71
Upside: +40.81%
MeiraGTx Holdings
Mar 27, 2026
Maintains: Overweight
Price Target: $30 → $26
Current: $10.12
Upside: +156.92%
Tyra Biosciences
Mar 20, 2026
Maintains: Overweight
Price Target: $42 → $56
Current: $35.56
Upside: +57.48%
Scholar Rock Holding
Mar 4, 2026
Maintains: Overweight
Price Target: $51 → $58
Current: $49.96
Upside: +16.09%
Ionis Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $87 → $100
Current: $75.71
Upside: +32.08%
Travere Therapeutics
Feb 6, 2026
Maintains: Neutral
Price Target: $35 → $38
Current: $40.77
Upside: -6.79%
BioMarin Pharmaceutical
Feb 6, 2026
Maintains: Overweight
Price Target: $122 → $84
Current: $54.64
Upside: +53.73%
Incyte
Feb 6, 2026
Maintains: Overweight
Price Target: $102 → $110
Current: $97.82
Upside: +12.45%
Akebia Therapeutics
Feb 6, 2026
Maintains: Overweight
Price Target: $6 → $4
Current: $1.41
Upside: +184.70%
Replimune Group
Feb 5, 2026
Maintains: Overweight
Price Target: $13 → $14
Current: $2.17
Upside: +545.16%
Feb 5, 2026
Maintains: Overweight
Price Target: $3 → $4
Current: $1.67
Upside: +139.52%
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $849.04
Upside: +9.54%
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $120.16
Upside: -6.79%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $24.81
Upside: +363.52%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $8.07
Upside: +222.18%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $32.43
Upside: -29.08%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $29.83
Upside: -26.25%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $8.63
Upside: +131.75%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $4.01
Upside: +398.75%